Clinical Trial

Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial investigates how well brentuximab vedotin and bendamustine work in treating patients with follicular lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. Chemotherapy drugs, such as bendamustine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial is being done to determine if the combination of brentuximab vedotin plus bendamustine is safe and to determine the effectiveness of the combination.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2020-10-07; most recent amendment 2026-06-25.
Status change: Not Yet Recruiting → Recruiting 2020-12-09
Trial Details
NCT Number NCT04587687
Lead Sponsor University of California, Davis
Collaborators: National Cancer Institute (NCI), Seagen Inc.
Conditions Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma
Enrollment 23 participants
Start Date 2020-12-04
Primary Completion 2027-12 (estimated)
Study Completion 2028-05 (estimated)
Updated on ClinicalTrials.gov 2026-06-29